AMLo Biosciences
London, United Kingdom· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
AMLo Biosciences is a UK-based diagnostics company founded in 2017, translating cancer biomarker research into prognostic and companion diagnostic tests. Its initial focus is on improving risk stratification for melanoma and other skin and head & neck cancers to enable more personalized patient management and reduce healthcare costs. The company is developing its lead product, AMBLor®, a prognostic test for early-stage melanoma.
Diagnostics